...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oral diseases >BRAF V600E expression in ameloblastomas—A 36‐patient cohort from Helsinki University Hospital
【24h】

BRAF V600E expression in ameloblastomas—A 36‐patient cohort from Helsinki University Hospital

机译：Ameloblastomas的BRAF V600E表达 - 赫尔辛基大学医院的36例患者队列

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Objectives We aimed to investigate BRAF V600E percentage immunohistochemically in ameloblastomas of a single institute cohort. We were interested if age, location, histological properties, or tumor recurrence depend on the BRAF status. Subjects, materials and methods We had 36 formalin‐fixed, paraffin‐embedded ameloblastoma tissue samples of patients treated at the Helsinki University Hospital between the years 1983–2016. Tissue sections underwent immunohistochemistry by Ventana BenchMark XT immunostainer using Ms Anti‐Braf V600E (VE1) MAB. We used R 3.4.2 and RStudio 1.1.383 to conduct statistical analysis for BRAF positivity and earlier onset as well as tumor location. We used chi‐squared tests and 2‐by‐2 table functions to determine connections between BRAF positivity and recurrence, growth pattern, and type. Results BRAF‐positive tumors occurred in younger patients compared to BRAF‐negative tumors ( p?=? 0.015) and they located mostly to the mandible ( p ??0.001). Growth patterns were limited to two in BRAF‐negative tumors when BRAF‐positive tumors presented with one to four growth patterns ( p?=? 0.02). None of the maxillary tumors showed BRAF positivity and of these, 72.2% recurred. Conclusions An immunohistochemical BRAF marker could be a beneficial tool to predict the outcome of patients with this aggressive, easily recurring tumor.
机译：摘要目标我们旨在在单一学院队列的亚利母细胞组织中调查BRAF V600E百分比。如果年龄，位置，组织学特性或肿瘤复发，我们对我们感兴趣，取决于BRAF状态。我们在1983 - 2016年赫尔辛基大学医院治疗的患有36名福尔马林固定的石蜡包埋的甲烷烃嵌入式母细胞瘤组织样本。组织切片通过Ventana基准XT免疫蛋白剂使用MS抗BRAF V600E（VE1）MAB进行免疫组织化学。我们使用R 3.4.2和Rstudio 1.1.383对BRAF积极性和早期发作以及肿瘤位置进行统计分析。我们使用Chi-Squared测试和2×2表函数来确定BRAF积极性和复发，生长模式和类型之间的连接。结果与BRAF阴性肿瘤相比，患者的BRAF阳性肿瘤发生（p？= 0.015），它们主要位于下颌骨（p≤≤0.001）。当用一至四个生长模式呈现的BRAF阳性肿瘤时，生长模式限于BRAF阴性肿瘤中的两个（P？= 0.02）。没有一个上颌肿瘤显示BRAF积极性，其重复72.2％。结论免疫组织化学BRAF标记可能是预测这种侵略性，容易反复肿瘤的患者的结果的有益工具。

著录项

  • 来源
    《Oral diseases》 |2019年第4期|共6页
  • 作者

    Kelppe Jetta; Thorén Hanna; Ristim?ki Ari; Haglund Caj; Sorsa Timo; Hagstr?m Jaana;

  • 作者单位

    Department of PathologyUniversity of Helsinki and Helsinki University HospitalHelsinki Finland;

    Department of Oral and Maxillofacial Surgery Institute of DentistryUniversity of TurkuTurku Finland;

    Department of Pathology HUSLABHelsinki University Hospital and Genome‐Scale Biology Research;

    Department of SurgeryUniversity of Helsinki and Helsinki University HospitalHelsinki Finland;

    Department of Oral and Maxillofacial Diseases Head and Neck CentreUniversity of Helsinki and;

    Department of PathologyUniversity of Helsinki and Helsinki University HospitalHelsinki Finland;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 口腔科学;
  • 关键词

    ameloblastoma; BRAF; immunohistochemistry;

    机译：aselflastoma;漂亮的;免疫组化;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号